1. Home
  2. SUPX vs CGEN Comparison

SUPX vs CGEN Comparison

Compare SUPX & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SUPX

Super X AI Technology Limited Ordinary Shares

HOLD

Current Price

$8.06

Market Cap

336.4M

Sector

N/A

ML Signal

HOLD

Logo Compugen Ltd.

CGEN

Compugen Ltd.

HOLD

Current Price

$2.88

Market Cap

270.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SUPX
CGEN
Founded
2021
1993
Country
Singapore
Israel
Employees
40
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
336.4M
270.4M
IPO Year
N/A
2001

Fundamental Metrics

Financial Performance
Metric
SUPX
CGEN
Price
$8.06
$2.88
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$5.00
AVG Volume (30 Days)
374.3K
541.7K
Earning Date
05-14-2026
05-18-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$75.09
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.61
$1.29
52 Week High
$76.00
$3.24

Technical Indicators

Market Signals
Indicator
SUPX
CGEN
Relative Strength Index (RSI) 48.85 59.63
Support Level $6.76 $1.45
Resistance Level $11.42 $3.24
Average True Range (ATR) 1.10 0.17
MACD 0.00 -0.02
Stochastic Oscillator 23.23 48.58

Price Performance

Historical Comparison
SUPX
CGEN

About SUPX Super X AI Technology Limited Ordinary Shares

Super X AI Technology Ltd is an AI infrastructure solutions provider. Through its subsidiaries, SuperX offers a comprehensive portfolio of proprietary hardware, advanced software, and end-to-end services for AI data centers. The Company's services include advanced solution design and planning, cost-effective infrastructure product integration, and end-to-end operations and maintenance. Its core products include high-performance AI servers, High-Voltage Direct Current (HVDC) solutions, high-density liquid cooling solutions, as well as AI cloud and AI agents. The Company serves institutional clients globally, including enterprises, research institutions, and cloud and edge computing deployments.

About CGEN Compugen Ltd.

Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.

Share on Social Networks: